

REMARKS

Claims 99 and 108-111 were pending in the application. As indicated by the Examiner at page 3 of the present Office Action (dated January 4, 2008), claim 99 is allowable.

Claims 108-111 have been canceled without prejudice. Accordingly, upon entry of the amendments presented herein, claim 99 will remain pending in the application.

No new matter has been added. The foregoing claim cancellations should in no way be construed as acquiescence to any of the Examiner's rejections and were made solely to expedite prosecution of the application. Applicants reserve the right to pursue claims to the canceled subject matter, or any subject matter which they are entitled to claim, in this or a separate application.

Acknowledgment of the Examiner's Withdrawal of Certain Rejections

In the present Office Action, the Examiner did not specifically acknowledge withdrawal of the following rejections: (a) the prior rejection of claims 94 and 99-107 under 35 U.S.C. §112, first paragraph, as containing new matter; (b) the prior rejection of claims 94 and 99-107 under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement; and (c) the prior rejection of claims 94 and 99-107 under 35 U.S.C. §112, first paragraph, as lacking enablement. However, in view of the Examiner's statement on page 2, paragraph 3 of the present Office Action that "all previous rejections have been withdrawn," Applicants respectfully assume that these rejections have been withdrawn.

Rejection of Claims 108-111 under 35 U.S.C. § 112, First Paragraph – New Matter

Claims 108-111 are rejected as containing new matter. Although the Examiner acknowledges that the specification and claims as originally filed provide support for a human antibody comprising both SEQ ID NO:2 and SEQ ID NO:4, the Examiner alleges that the specification and claims do not provide support for an antibody defined only by SEQ ID NO:2 or SEQ ID NO:4 or any antibody defined by both SEQ ID NOs:2 and 4.

Applicants respectfully traverse this rejection. Specifically, support for anti-human dendritic cell monoclonal antibodies defined by a particular heavy and/or light chain variable region sequence (*i.e.*, SEQ ID NOs:4 or 2, respectively) can be found, at least, for example, in Figure 13 and original claim 51. Notwithstanding, Applicants have canceled claims 108-111 to

expedite prosecution, thereby rendering this rejection moot. Accordingly, Applicants respectfully request that the Examiner reconsider and withdraw the foregoing rejection.


CONCLUSION

Based on the foregoing amendment, reconsideration and withdrawal of all rejections and allowance of this application is respectfully requested. If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-166RCE2.

Dated: January 23, 2008

Respectfully submitted,


By
Jill Gorny Sloper
Registration No.: 60,760
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicants